Aclaris Therapeutics (ACRS) Competitor Comparison
We are evaluating the key criteria listed to compare Aclaris Therapeutics (ACRS) against its competitors in the Biotechnology industry.
Market Capitalization
271 / 368Gross Profits
207 / 278Total Revenue
162 / 300EBITDA
0 / 337Free Cashflow
221 / 352Quick Ratio
232 / 357Earnings per Share
88 / 359Dividend yield
0 / 6Total Cash
212 / 358Performance 3 years
262 / 368Performance 5 years
86 / 368Performance 10 years
195 / 368Linearity 3 years
148 / 368Linearity 5 years
19 / 368Linearity 10 years
93 / 368Total Rank
110 / 368Dividend Rank
327 / 368Valuation Rank
177 / 368Piotroski Rank
37 / 368Muliplier Rank
36 / 368Linearity 3 years - ACRS ranking 148 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.